Scholarlink

Introduction <p>Rett syndrome (RTT) is a rare neurodevelopmental disease that primarily affects females but also occurs in males. Trofinetide (TROF) is approved in the USA and Canada for individuals with RTT regardless of sex aged ≥ 2&#xa0;years; efficacy and safety of TROF was primarily studied among females, thus real-world data for males remain limited. This study evaluated real-world characteristics, treatment persistence, and predictors of non-persistence among males with RTT.</p> Methods <p>This retrospective cohort study using IQVIA database linked to TROF specialty pharmacy claims from 01/01/2021 to 09/30/2024 identified males with ≥ 1 medical claim for RTT (ICD-10 F84.2). Two groups were created based on treatment status and their respective index dates: treated and untreated. Continuous enrollment of ≥ 6&#xa0;months pre-index and post-index was required. Pre-index demographics and clinical characteristics were compared descriptively. Among treated males, Kaplan–Meier analysis assessed time to non-persistence, and logistic regression evaluated predictors of non-persistence.</p> Results <p>Of 8047 individuals with RTT identified in the database,&#xa0;1219 (15.1%) were males; of these, 75 (6.2%) were treated with TROF and 1144 (93.8%) were untreated; after final study criteria, 51 (10.9%) were treated and 415 (89.1%) were untreated. The mean (SD) age for treated vs untreated males was 18.8 (18.3) vs 17.7 (13.2) years. Neurologists managed most patients treated with TROF (64.7% vs 12.7%). Treated males had higher pre-index rates of epilepsy (52.9% vs 25.5%), gastrostomy (31.4% vs 16.1%), and respiratory failure (25.5% vs 13.3%) than untreated (all <i>p</i> &lt; 0.05). Among treated males, 52.9% were persistent and 47.1% were non-persistent. Approximately 70% remained on TROF for ≥ 6&#xa0;months and &gt; 50% for ≥ 17&#xa0;months. Pre-index neurologic disorders were significantly associated with non-persistence.</p> Conclusions <p>Most males with RTT remained untreated during this study period, while TROF initiation appeared concentrated among those with greater pre-index concomitant comorbidities and neurology involvement. Persistence beyond 6&#xa0;months was common, supporting continued long-term use of TROF in males with RTT in real-world practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World Demographics, Clinical Characteristics, and Predictors of Persistence Among Males with Rett Syndrome Treated with Trofinetide

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月30日

查看全文
  • Krithika Rajagopalan,
  • Vinod Yakkala,
  • Nazia Rashid

摘要

Introduction

Rett syndrome (RTT) is a rare neurodevelopmental disease that primarily affects females but also occurs in males. Trofinetide (TROF) is approved in the USA and Canada for individuals with RTT regardless of sex aged ≥ 2 years; efficacy and safety of TROF was primarily studied among females, thus real-world data for males remain limited. This study evaluated real-world characteristics, treatment persistence, and predictors of non-persistence among males with RTT.

Methods

This retrospective cohort study using IQVIA database linked to TROF specialty pharmacy claims from 01/01/2021 to 09/30/2024 identified males with ≥ 1 medical claim for RTT (ICD-10 F84.2). Two groups were created based on treatment status and their respective index dates: treated and untreated. Continuous enrollment of ≥ 6 months pre-index and post-index was required. Pre-index demographics and clinical characteristics were compared descriptively. Among treated males, Kaplan–Meier analysis assessed time to non-persistence, and logistic regression evaluated predictors of non-persistence.

Results

Of 8047 individuals with RTT identified in the database, 1219 (15.1%) were males; of these, 75 (6.2%) were treated with TROF and 1144 (93.8%) were untreated; after final study criteria, 51 (10.9%) were treated and 415 (89.1%) were untreated. The mean (SD) age for treated vs untreated males was 18.8 (18.3) vs 17.7 (13.2) years. Neurologists managed most patients treated with TROF (64.7% vs 12.7%). Treated males had higher pre-index rates of epilepsy (52.9% vs 25.5%), gastrostomy (31.4% vs 16.1%), and respiratory failure (25.5% vs 13.3%) than untreated (all p < 0.05). Among treated males, 52.9% were persistent and 47.1% were non-persistent. Approximately 70% remained on TROF for ≥ 6 months and > 50% for ≥ 17 months. Pre-index neurologic disorders were significantly associated with non-persistence.

Conclusions

Most males with RTT remained untreated during this study period, while TROF initiation appeared concentrated among those with greater pre-index concomitant comorbidities and neurology involvement. Persistence beyond 6 months was common, supporting continued long-term use of TROF in males with RTT in real-world practice.